Seelos Therapeutics (SEEL) Competitors $0.27 -0.02 (-8.03%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SEEL vs. NEXI, PRFX, TCBP, TFFP, BLPH, TCON, SMFL, CLVR, VAXX, and NAVBShould you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include NexImmune (NEXI), PainReform (PRFX), TC Biopharm (TCBP), TFF Pharmaceuticals (TFFP), Bellerophon Therapeutics (BLPH), TRACON Pharmaceuticals (TCON), Smart for Life (SMFL), Clever Leaves (CLVR), Vaxxinity (VAXX), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry. Seelos Therapeutics vs. NexImmune PainReform TC Biopharm TFF Pharmaceuticals Bellerophon Therapeutics TRACON Pharmaceuticals Smart for Life Clever Leaves Vaxxinity Navidea Biopharmaceuticals Seelos Therapeutics (NASDAQ:SEEL) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability. Do institutionals and insiders have more ownership in SEEL or NEXI? 23.4% of Seelos Therapeutics shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 1.1% of Seelos Therapeutics shares are held by company insiders. Comparatively, 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, SEEL or NEXI? Seelos Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Does the media prefer SEEL or NEXI? In the previous week, Seelos Therapeutics' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment Seelos Therapeutics Neutral NexImmune Neutral Does the MarketBeat Community believe in SEEL or NEXI? Seelos Therapeutics received 49 more outperform votes than NexImmune when rated by MarketBeat users. Likewise, 66.36% of users gave Seelos Therapeutics an outperform vote while only 61.11% of users gave NexImmune an outperform vote. CompanyUnderperformOutperformSeelos TherapeuticsOutperform Votes7166.36% Underperform Votes3633.64% NexImmuneOutperform Votes2261.11% Underperform Votes1438.89% Is SEEL or NEXI more profitable? Seelos Therapeutics has a net margin of 203.13% compared to NexImmune's net margin of 0.00%. Seelos Therapeutics' return on equity of 0.00% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets Seelos Therapeutics203.13% N/A -431.47% NexImmune N/A -534.32%-213.72% Which has stronger valuation & earnings, SEEL or NEXI? NexImmune has lower revenue, but higher earnings than Seelos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeelos Therapeutics$2.20M0.05-$37.88MN/AN/ANexImmuneN/AN/A-$32.34M-$18.54-0.01 SummarySeelos Therapeutics beats NexImmune on 7 of the 10 factors compared between the two stocks. Ad Crypto 101 MediaThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide… You can get access to the report by clicking here now… Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEEL vs. The Competition Export to ExcelMetricSeelos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99,000.00$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.1317.19Price / Sales0.05196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.005.094.784.78Net Income-$37.88M$151.83M$120.31M$225.60M7 Day Performance-9.59%-2.14%-1.92%-1.23%1 Month Performance-46.12%-4.56%13.65%0.46%1 Year Performance-99.87%8.87%28.34%15.24% Seelos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEELSeelos TherapeuticsN/A$0.27-8.0%N/A-99.8%$99,000.00$2.20M0.0020NEXINexImmuneN/A$0.30+30.4%N/A-89.7%$418,000.00N/A-0.016PRFXPainReform1.7798 of 5 stars$2.89-7.1%$8.00+176.8%-47.6%$405,000.00N/A-0.024News CoverageGap DownTCBPTC Biopharm2.9827 of 5 stars$0.55+3.2%$3.00+449.8%-97.4%$289,000.00$4.76M0.0041News CoverageGap DownTFFPTFF Pharmaceuticals2.1531 of 5 stars$0.07flat$44.00+67,592.3%N/A$289,000.00$730,000.00-0.0119Positive NewsBLPHBellerophon Therapeutics0.8459 of 5 stars$0.02+55.7%N/A-62.5%$232,000.00$5.64M-0.0220Dividend AnnouncementAnalyst ForecastNews CoverageGap UpTCONTRACON Pharmaceuticals0.9609 of 5 stars$0.03-26.0%$60.00+186,235.4%-99.1%$110,000.00$12.05M0.0120Gap DownSMFLSmart for LifeN/A$0.01+39.6%N/A-99.9%$100,000.00$8.23M0.00110Gap UpCLVRClever LeavesN/A$0.03flatN/A-100.0%$48,000.00$17.42M0.00560VAXXVaxxinityN/A$0.00+100.0%N/A-100.0%$25,000.00$70,000.000.0090NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst Forecast Related Companies and Tools Related Companies NEXI Competitors PRFX Competitors TCBP Competitors TFFP Competitors BLPH Competitors TCON Competitors SMFL Competitors CLVR Competitors VAXX Competitors NAVB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEEL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
